# A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

> **NCT00216502** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag S.p.A.** · enrollment: 254 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia
- Mental Disorders
- Brain Diseases

## Interventions

- **DRUG:** galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00216502
- **Lead sponsor:** Janssen-Cilag S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216502, "A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00216502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*